| Name | S 3304 |
| Description | S 3304 is a novel matrix metalloproteinase inhibitor, specifically targeting MMP-2 and MMP-9. |
| In vitro | S 3304 is a novel D-tryptophan derivative and a potent, noncytotoxic matrix metalloproteinase inhibitor. It most effectively inhibits MMP-2 and MMP-9 activities but does not inhibit MMP-1, MMP-3, or MMP-7, potentially avoiding the musculoskeletal side effects associated with nonspecific inhibitors [1]. |
| In vivo | S 3304 (p.o., the dose range of 20 to 200 mg/kg) treatment, inhibits angiogenesis, artificially induced in mice by the dorsal air-sac method. Similar oral doses of S 3304 cause effective inhibition of metastatic lung colonization of Lewis murine lung carcinoma injected via tail vein and liver metastasis of C-1H human colon cancer implanted into the spleen [1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (7.1 mM), Sonication is recommended.
DMSO : 83.3 mg/mL (179.31 mM), Sonication is recommended.
|
| Keywords | S-3304 | S3304 | S 3304 | MMP-9 | MMP-2 | MMP | Matrix metalloproteinases | Inhibitor | inhibit |
| Inhibitors Related | Rhamnose monohydrate | Doxycycline (hyclate) | Chondroitin sulfate | Astragaloside IV | Doxycycline | Edaravone | Glucosamine | Anethole | Meloxicam | Chloramphenicol | Propoxur | Methylchloroisothiazolinone/Methylisothiazolinone Mixture |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Protease Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Angiogenesis related Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Fibrosis Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
